Brazil suspended the administration of the Butantan Institute's dengue vaccine on June 8 [1], [2].
The temporary halt follows reports of severe adverse reactions, including suspected fatalities, which could impact the national strategy to combat the mosquito-borne virus.
The Ministry of Health and the Butantan Institute initiated the suspension after identifying 42 patients who presented alarm signs [1], [2]. Authorities have also recorded 3,703 notifications of adverse effects [1]. Most concerning to officials are two suspected deaths associated with the vaccine [1].
Officials are now conducting a new phase of investigation to determine the exact causes of these reactions [2]. The suspension applies across the entire national territory of Brazil [1], [2].
While the current investigation focuses on severe cases, experts had previously noted that the vaccine can cause mild and temporary reactions. An immunology specialist said the application of the dengue vaccine may cause light reactions as a sign that the immune system is creating necessary defenses [3].
However, the scale of the current reports triggered the emergency stop. "The Ministry of Health temporarily interrupts the application of the immunizer after records of serious events," TVCenário said [2].
Some observers suggest the move demonstrates the effectiveness of the country's health monitoring. An unidentified specialist said the suspension is not a failure, but the system functioning [4].
“The suspension is not a failure, but the system functioning”
The suspension reflects a critical tension between the urgency of dengue prevention and the stringent requirements of vaccine safety monitoring. By halting the rollout following 3,703 adverse effect notifications, Brazil is prioritizing the precautionary principle to avoid a broader public health crisis or a permanent loss of public trust in the immunization program.
